Healthcare Jan 12, 2023 10:53 AM (GMT+8) · EqualOcean
Bioantibody Biotechnology (Chinese: 佰抗生物), a fast-growing IVD company focusing on the R&D and production of antigens, antibodies and downstream detection reagents for diagnosis and therapy, announced its completion of a CNY 100 millions Series A round of financing. This round was led by Fang Fund Partners (Chinese: 芳晟基金) and followed by NII Capital (Chinese: 新工产投), Guoqian Venture Capital (Chinese: 国仟创投), and Bondshine Capital (Chinese: 邦盛资本). PhoenixTree Capital (Chinese: 青桐资本) served as the exclusive financial adviser. After this proceeding, Bioantibody will continue to increase R&D investment, develop more high quality raw materials, accelerate the global market deployment, and assist downstream clients in the development of more medical products.